Click to view your profile
Click to search for condition or expert
Click to open main menu
Multiple Myeloma Latest Advances
Find the Latest Research About Multiple Myeloma
Save
Bookmark
Share
Share
Overview
Find a Doctor
Latest Advances
Clinical Trials
Treatments
Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/06/2023
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 648 publications
See more filters
Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.
Condition:
Triple-Negative/Her2( +) Breast Cancer, Multiple Myeloma, and Non-Small-Cell Lung Cancer
Journal:
Journal of the Egyptian National Cancer Institute
Treatment Used:
Combination Immunotherapy and Chemotherapy
Published:
January 01, 2023
VIEW PUBLICATION
Next-Generation Chimeric Antigen Receptor T-cells.
Condition:
B-Cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)
Journal:
Hematology/oncology and stem cell therapy
Treatment Used:
CAR T-Cell Therapy
Published:
December 20, 2022
VIEW PUBLICATION
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
Condition:
Multiple Myeloma
Journal:
Journal of medical case reports
Treatment Used:
LCAR-B38M Chimeric Antigen Receptor T Cells
Number of Patients:
1
Published:
December 10, 2022
VIEW PUBLICATION
The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Condition:
Relapsed/Refractory Multiple Myeloma (RRMM)
Journal:
Annals of hematology
Treatment Used:
Teclistamab, Elranatamab, and Talquetamab
Published:
December 03, 2022
VIEW PUBLICATION
Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years.
Condition:
Relapsed/Refractory Multiple Myeloma (MM)
Journal:
Anticancer research
Treatment Used:
Autologous Stem Cell Transplantation (auto-SCT)
Number of Patients:
75
Published:
December 01, 2022
VIEW PUBLICATION
SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia.
Condition:
Acute Myeloid Leukemia (AML)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Maintenance Therapy
Published:
December 01, 2022
VIEW PUBLICATION
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
Condition:
Relapsed/Refractory (R/R) Multiple Myeloma (MM)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Cobimetinib Alone and Plus Venetoclax with/without Atezolizumab
Number of Patients:
49
Published:
November 30, 2022
VIEW PUBLICATION
The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Condition:
Relapsed/Refractory Multiple Myeloma
Journal:
European review for medical and pharmacological sciences
Treatment Used:
Triplet Regimens Based on Pomalidomide and Dexamethasone
Number of Patients:
1889
Published:
November 17, 2022
VIEW PUBLICATION
Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.
Condition:
Multiple Myeloma (MM)
Journal:
Biomolecules
Treatment Used:
Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib
Number of Patients:
0
Published:
November 11, 2022
VIEW PUBLICATION
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Condition:
Relapsed/Refractory Multiple Myeloma (RRMM)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Ciltacabtagene Autoleucel
Number of Patients:
36
Published:
November 10, 2022
VIEW PUBLICATION
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Condition:
Multiple Myeloma
Journal:
The Lancet. Haematology
Treatment Used:
Isatuximab Added to Lenalidomide, Bortezomib, and Dexamethasone
Number of Patients:
660
Published:
November 03, 2022
VIEW PUBLICATION
Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma.
Condition:
Relapsed/Refractory Multiple Myeloma (RRMM)
Journal:
Zhonghua yi xue za zhi
Treatment Used:
Daratumumab
Number of Patients:
52
Published:
November 01, 2022
VIEW PUBLICATION
Showing 1-12 of 648
Next
Last Updated: 01/06/2023